Clinical Trial Update: Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating IdeS for anti-GBM disease has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-glomerular Basement Membrane Antibody Disease

Drugs mentioned

• IdeS (Immunoglobulin-degrading enzyme of Streptococcus pyogenes)

Snippet

Sponsor: Mårten Segelmark | Conditions: Anti-Glomerular Basement Membrane Antibody Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-04-07